Clinical Trial

Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD

Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of the study is to evaluate belumosudil pharmacokinetics of whole tablets and crushed tablets suspended in water in patients suffering from chronic graft-versus-host disease (cGVHD).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-11; most recent amendment 2026-02-16.
Status change: Not Yet Recruiting → Recruiting 2026-02-16
Trial Details
NCT Number NCT07127926
Lead Sponsor M.D. Anderson Cancer Center
Conditions Chronic Graft Versus Host Disease
Enrollment 8 participants
Start Date 2026-02-09
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-18